

# Leveraging advanced technologies for improved cardiac sparing

**Carri Glide-Hurst, PhD, DABR, FAAPM**

Director of Translational Research, Radiation Oncology  
Henry Ford Cancer Institute →

Director, Radiation Oncology Physics, Department of Human Oncology,  
University of Wisconsin Madison



# Disclosures

- Research funding provided by:
  - NIH R01CA204189 (PI: Glide-Hurst)
  - Philips Healthcare
- Collaborations with Modus Medical Devices, ViewRay (unrelated to the current work)
- Many of these slides are compliments of the recently minted Dr. Eric Morris (HFCI/WSU—>UCLA)




How is the heart  
like bowling?




# Clinical Motivation: Cardiac Dose

- Radiation dose to the heart may be fatal<sup>1</sup>
- **Hodgkin's lymphoma**<sup>2</sup>
  - Myocardial infarction
- **Esophageal**<sup>3</sup>
  - Heart failure
- **Advanced stage lung**<sup>4</sup> and **breast**<sup>1</sup>
  - Coronary artery disease: Left > Right



1 . Darby et al., NEJM, 2013; 2. Ng et al., BrJH, 2011; 3. Beukema et al., RO, 2015; 4. Hardy et al., AO, 2010.

# Deep-inspiration Breath Hold (DIBH)



- Surface monitoring (RPM, AlignRT, bellows, SDX)
- Spirometry (ABC)

Rong et al, Plos One, 2014



# Limitations in Heart Dose/Volume Metrics

- RTOG 0617: 74 Gy (2 Gy fx) w/ concurrent chemo was **not** better than 60 Gy
  - Might be **potentially harmful** (!!!)
- RTOG 0617 heart dose-volume thresholds for treatment planning:
  - Heart V33% < 60 Gy; V66% < 45 Gy; V100% < 40 Gy
- Lowest priority among all normal tissues
- QUANTEC endpoint: <10% of heart receives >25 Gy for long-term cardiac mortality endpoints



# Whole-heart Dose Metrics are not Sensitive

Original Clinical Plan
Cardiac Spared Plan
Dose (Gy)

Practical Radiation Oncology® (2020) 10, e147–e154



www.practicalradonc.org

Basic Original Report

## The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era

Bradford S. Hoppe, MD, MPH,<sup>a,\*</sup> James E. Bates, MD,<sup>b,c</sup>  
 Nancy P. Mendenhall, MD,<sup>b,c</sup> Christopher G. Morris, MS,<sup>b,c</sup>  
 Debbie Louis, CMD,<sup>b</sup> Meng Wei Ho, MS,<sup>b</sup> Richard T. Hoppe, MD,<sup>d</sup>  
 Marwan Shaikh, MD,<sup>e</sup> Zuofeng Li, DSc,<sup>b,c</sup> and Stella Flampouri, PhD<sup>b,c</sup>

<sup>a</sup>Mayo Clinic Florida, Department of Radiation Oncology, Jacksonville, Florida; <sup>b</sup>University of Florida Health Proton Therapy Institute, Jacksonville, Florida; <sup>c</sup>Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida; <sup>d</sup>Department of Radiation Oncology, Stanford University, Palo Alto, California; and <sup>e</sup>Department of Hematology/Oncology, University of Florida College of Medicine

60

50

40

30

20

Abs Diff
-2.7
2.1
1.4
-0.1
6.4
5.5
15.9
3.0

2

LV-V5 (%)	30.6	14.7	15.9
LADA Max (Gy)	10.0	7.0	3.0

Heart	LV	RV	LA	AA	SVC	PV	RA	LMCA	LADA
-------	----	----	----	----	-----	----	----	------	------

# Clinical Motivation: Cardiac Substructure Doses


- RTOG 0617 sub-analysis suggests dose to substructures were more strongly associated with overall survival than standard of care whole-heart dose estimates<sup>1</sup>
- Left atrium/ventricle (LA/LV) & left anterior descending artery (LADA) have prognostic inferences, such as: **Risk of cardiomyopathy, CAD, ischemic diseases, etc.**<sup>2</sup>
- Recent dose constraints to substructures have been introduced<sup>3</sup>

Structure	Constraint	Value
Whole Heart	Mean Heart Dose	< 2.5 Gy
LV	LADA-V40	< 1%
	Mean LV Dose	< 3 Gy
LADA	LV-V5	< 17%
	LADA maximum dose	< 10 Gy

all for

# Substructure Atlas Generation & Application in MIM

- 20 left-sided breast cancer patients, cardiac T2-weighted MRI at 3T and TPCTs
- 15 patients in the atlas, 5 test subjects
- Compared (1) single-atlas, (2) majority vote (MV), and (3) simultaneous truth & performance level estimation (STAPLE)
- Atlas subject selected via mutual information, then contours deformably registered
- Multi-atlas matches iterated (1, 3, 5, 10, and 15)



Morris et al,  
IJROP, 2019




# Single Validation Patient: ST10 vs. Ground Truth Contours

DSC > 0.75


DSC < 0.55

Posterior




Right

Superior




Inferior



Left



# Deep Learning 3D U-Net Architecture





- Paired MRI/CT data for 25 patients were placed into separate image channels to train network
- Novel Deep Learning Contributions<sup>1</sup>:** Multi-channel (MRI/CT) inputs, deep supervision, 3D adaptation on original 2D U-Net<sup>2</sup>, and hyperparameter optimization



# Results: Worst Case

2D Axial

Ground Truth




DL Prediction






3D Rendering

Sagittal



Coronal



LV

RV

LA

RA

SVC

IVC

PV


PA

AA


RCA

LADA

# Results: Comparison to Multi-Atlas Method



Cardiac Substructure




Cardiac Substructure

**~14 seconds (DL) vs. ~10 minutes (multi-atlas)**




# Cardiac Substructure Motion During Respiration



# Dose Variations During Respiration


- Note small variations for the whole heart (red), mean dose < 0.5 Gy (not sensitive!!)
- Superior vena cava mean dose > 5 Gy difference

PO-GeP-M-96  
Miller, C. et al.




# Substructure Spared Planning, IMRT

Original Esophageal Plan



Revised Beam Angles



Dose (Gy)

30.0

25.0

20.0

15.0

10.0

5.0

LV

RV

LA

RA

RCA


LADA

PTV

- Exceptional sparing to the LADA
- New beam arrangements possible with 4/16 patients



# Results: Patient DVH with Beam Modification




- Negligible increase in estimated delivery time with re-optimized plans ( $0.1 \pm 1.3$  min, with 12/16 plans having  $<100$  MU change)




# Substructure spared planning: VMAT, Protons





VMAT  
2-4 Arcs



CARDIAC  
SPARED  
VMAT  
2-4 Arcs




PROTONS  
2-3 beams  
IMPT




60 Gy  
45 Gy  
30 Gy

# Cardiac Displacement Visualized in MR-guided RT



Substructure	SIM	Fx3	Dose (Gy)
Heart	Blue	Blue	45
RV	Red	Red	40
LV	Green	Green	30
RA	Yellow	Yellow	20
LA	Purple	Purple	10
AA	Cyan	Cyan	5
LADA	Orange	Orange	
RCA	Brown	Brown	
PV	Pink	Pink	



MO-F-TRACK 2-1\*  
 Morris, E. et al



# Clinical Impact & Conclusions

- Radiation therapy dose to the heart is avoidable and modifiable: we can (and should!) do better
- Becomes of even greater importance with dose escalation, hypofractionation, etc.
- Applying advanced technologies will help us keep our patients safer from acute and late cardiac toxicities

